Influence of immunosuppression on the prevalence of XXXX after kidney transplantation.

@entity1 @entity2826 @entity500 @entity5 @entity229 @entity1489 @entity205 @entity281 @entity1578 @entity65 @entity1140 @entity10002 @entity204
The prevalence of @entity5 in renal transplant @entity1 is greater than in the general population. It is influenced by demographic and ethnic characteristics. We performed a retrospective study of 793 @entity1 who received 872 kidney transplants at our center during 23 years. The age at transplantation was 41.4+/-14.0 years, the follow up 75.4+/-69.4 months. The cohorts include 203 @entity1 treated with @entity500 - @entity229 ; 510, @entity205 -based therapy; and 159, @entity1140 -based therapy. There were 95 @entity1 (10.9%) who developed at least one @entity5 with 9 having more than one type of @entity5 . The incidence was of 17.3 cases per 1000 @entity1 -years. Forty-four (46.3%) had @entity1489 , 8 (8.4%) @entity2826 and 43 (45.3%) a @entity1489 . Seven of eight @entity1 with @entity2826 were on @entity10002 therapy. The risk of developing a @entity5 at 5, 10, and 15 years was 8%, 17%, and 30% respectively. In a multivariate analysis, the risk factors associated with @entity5 were older age (OR=1.061; 95% CI 1.039-1.084; P=.000), male sex (OR=2.658; 95% CI 1.536-4.599; P=.000), length of follow-up (OR=1.121; 95% CI 1.073-1.172; P =.000), and immunosuppression with @entity10002 (OR=4.448; 95% CI 1.334-14.764; P=.015). @entity5 was the cause of @entity204 in 26 @entity1 , the fourth most common cause after @entity65 , @entity281 , and @entity1578 . We conclude that @entity5 are an important cause of morbidity and mortality among transplant @entity1 . Special attention must be devoted to older male @entity1 with a long-term follow up to develop preventive and surveillance strategies.
